Using rIL-2 and FAA to Treat Advanced Melanoma
Author Information
Author(s): A.K. Ghosh, M. Mellor, J. Prendiville, N. Thatcher
Primary Institution: Paterson Institute for Cancer Research and Christie Hospital
Hypothesis
Can recombinant interleukin-2 (rIL-2) combined with flavone acetic acid (FAA) enhance immunological responses in patients with advanced malignant melanoma?
Conclusion
The combination of rIL-2 and FAA increased NK cell activity in many patients, but did not significantly improve cytotoxicity compared to rIL-2 alone.
Supporting Evidence
- 23 out of 26 patients showed increased NK activity after treatment.
- LAK activity was induced in 13 out of 26 patients.
- Five patients had a tumor response, including one complete response.
Takeaway
Doctors tested a new treatment for skin cancer using two medicines together, and while it helped some patients' immune systems, it didn't work better than just one medicine alone.
Methodology
Patients received rIL-2 and FAA, and their NK and LAK cell activities were measured before and after treatment.
Limitations
The study did not find a significant correlation between immunological parameters and clinical outcomes.
Participant Demographics
34 patients (19 male, 15 female) with progressive metastatic melanoma.
Want to read the original?
Access the complete publication on the publisher's website